Phase 2 N=30 The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy
Milk Allergy
Primary: Change in CM-specific Immunogloblin E (IgE) — 0.8; -13.5; -9.4 kUa/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer
Non-Small Cell Lung Cancer · Colorectal Cancer
Primary: Overall Response Rate — 1 Participants
Phase 2 N=46 Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults
Chronic Hepatitis C · Hepatitis C (HCV) · Hepatitis C Genotype 1a
Primary: Slope of the Second Phase Decline in Plasma HCV Ribonucleic Acid (RNA) Levels During Treatment — 0.0036; 0.0046; 0.0051 1/day — p=0.311
Phase 2 N=50 Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults
HIV Infections · Lipodystrophy · Metabolic Diseases
Primary: Change in Fat mtDNA Content — -169; 321 copies/cell
Phase 2 N=45 Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder
HIV Associated Neurocognitive Disorder
Primary: Change in CSF Ceramide Between Baseline and Week 24 (C18:0 Levels) - Intent to Treat — -30.78; 4.16; -12.17; -30.56 ng/mL — p=0.893
Phase 2 N=27 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Acute Myelocytic Leukemia · Acute Lymphocytic Leukemia · Chronic Myelogenous Leukemia
Primary: Safety and Tolerability of HSC835 for Clinical Use Were Measured by Infusional Toxicity (Within First 48 Hours After Transplant) and Absence of Graft Failure After 32…
Phase 2 N=536 The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)
HIV Infections
Primary: Proportion of Sexual Exposures Covered by Pre- and Post-exposure Dosing — 75; 56; 52; 85 percentage of sexual exposures
Phase 2 N=84 A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Deep Vein Thrombosis · Venous Thrombosis
Primary: Relative Change From Baseline in Thrombus Volume Assessed by MRI [Using the Magnetic Resonance Venography (MRV) Method] — -46.6; -51.4 percentage of change
Phase 2 N=6 Anakinra for Behcet s Disease
Autoimmune Connective Tissue Disorder · Immune System Diseases
Primary: Clinical Remission From Months 3-6 — 2 Participants
Phase 2 N=44 Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment
Graft Versus Host Disease
Primary: Number of Participants Experiencing Treatment Success — 8 Participants
Phase 2 N=181 Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index
Elevated Body Mass Index
Primary: Part 1: Percent Change in Body Weight From Baseline to Week 12 — -5.51; 0.19; -6.55; 0.29 percent change — p=<0.001
Phase 2 N=40 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
Adult Alveolar Soft-part Sarcoma · Adult Angiosarcoma · Adult Epithelioid Sarcoma
Primary: Objective Tumor Response (Complete and Partial) — 2 Participants
Phase 2 N=46 Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
Mucopolysaccharidosis · Hurler Syndrome · Hunter Syndrome
Primary: Number of Patients With Donor Derived Engraftment — 42 Participants
Phase 2 N=37 Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
Lymphoma
Primary: Disease-Free Survival — 34; 30; 28; 25 Participants
Phase 2 N=218 A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Primary: Total Number of Gadolinium-Enhancing T1 Lesions Observed on Magnetic Resonance Imaging (MRI) Scans of the Brain — 5.6; 0.6; 0.2; 6.9 lesions — p=<0.0001